Therapeutic Digest


June 15, 2020

A silver lining of COVID-19 has been the necessary swift exchange of information as a response to a global public health crisis. The speed and volume of the scientific knowledge are correspondingly fast and unprecedented. We are at a unique time when competition among pharma companies and other entities have turned to collaboration and transparency. If the pharmaceutical industry continues to cooperate and aggregate its knowledge to flatten the pandemic curve, then a future without COVID-19 is truly at hand.

Post a Comment

You must be logged in to post a Comment.